NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with ...
In more than 700 chronic HCV patients without cirrhosis who were infected with one of genotypes 1-6 (GT1-6) and were new to treatment, 97.5 percent (n=693/711) achieved sustained virologic response at ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Of those who completed treatment, 92% had undetectable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results